TerminatedPhase 3

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

United States69 participantsStarted 2014-03

Plain-language summary

The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Completed either the X052130/CL3-78989-005 or the X052131/CL3-78989-006 study's masked D392 or OL-224 completion day visits or had controlled ocular inflammation after having received study drug in Part 2 of study X052133 Exclusion Criteria: * Discontinued from the previous study Other protocol-defined inclusion/exclusion criteria may apply

What they're measuring

Treatment-emergent Adverse Events

Timeframe: 108 weeks

Trial details

NCT IDNCT02258854

SponsorXOMA (US) LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-10

View on ClinicalTrials.gov More Uveitis trials